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Highlights 
 Mitochondrial dysfunction in PD triggers oxidative stress and energy failure  
 • We provide an integrated view of bioenergetics, redox and central carbon metabolism 
in PD  
 • Clinical trials demonstrate that PD cannot be explained simply by oxidative stress and 
energy failure  
 • These findings strengthen the idea that PD is a complex metabolic disorder  
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Abstract 
The loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the 
accumulation of protein inclusions (Lewy bodies) are the pathological hallmarks of Parkinson’s 
disease (PD). PD is triggered by genetic alterations, environmental/occupational exposures and 
aging. However, the exact molecular mechanisms linking these PD risk factors to neuronal 
dysfunction are still unclear. Alterations in redox homeostasis and bioenergetics (energy failure) 
are thought to be central components of neurodegeneration that contribute to the impairment of 
important homeostatic process in dopaminergic cells such as protein quality control 
mechanisms, neurotransmitter release/metabolism, axonal transport of vesicles and cell 
survival. Importantly, both bioenergetics and redox homeostasis are coupled to neuro-glial 
central carbon metabolism. We and others have recently established a link between the 
alterations in central carbon metabolism induced by PD risk factors, redox homeostasis and 
bioenergetics and their contribution to the survival/death of dopaminergic cells.  In this review, 
we focus on the link between metabolic dysfunction, energy failure and redox imbalance in PD, 
making an emphasis in the contribution of central carbon (glucose) metabolism. The evidence 
summarized here strongly supports the consideration of PD as a disorder of cell metabolism.  
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1. Introduction 
Oxidative stress and energy failure associated with mitochondrial dysfunction are cardinal 
hallmarks of neuronal cell death associated with neurodegenerative disorders [71, 215, 257, 
348]. Mitochondrial derived reactive oxygen species (ROS) contribute to neuronal cell death in 
neurodegeneration. However, the lack of success in the clinic of antioxidant-based therapies 
suggests that other contributors associated with mitochondrial dysfunction should also play an 
important role [1, 156, 225, 300]. Cellular bioenergetics is directly coupled with central carbon 
metabolism, and in the brain, glucose is the primary energy substrate.  Glucose metabolism has 
been shown to be altered in different neurodegenerative disorders. For example, in Alzheimer’s 
disease a disruption in glucose uptake and metabolism is found [59, 145, 341]. Hyperglycemia 
and amyloid  promote excitotoxicity in neuronal cells [7]. Other studies have also revealed that 
glucose metabolism is decreased in the cortex and basal ganglia of Huntington’s disease 
patients [69].  Interestingly, an increase in the levels of glucose transporters was found to 
correlate with a decreased age of onset in Huntington’s disease [327].  While cancer and 
diabetes/obesity are considered metabolic disorders clearly associated with a dysfunction in 
glucose metabolism, less is understood about the role of central carbon metabolism in 
neurodegeneration. Recently, we and others have revealed links between alterations in glucose 
metabolism and alterations in cellular bioenergetics, redox homeostasis and cell death 
progression induced by PD-related risk factors. In this review, we present an integrated 
overview of these results to evidence how alterations in central carbon metabolism have a 
central role in determining changes in cellular bioenergetics and redox homeostasis in PD.  
These findings are posed to make a significant contribution to our understanding of PD 
pathogenesis, and make a case for considering PD a metabolic disorder. 
2. Brain Metabolism, Bioenergetics and Redox Balance 
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2.1. Energy Metabolism in the Brain 
The brain can be considered the most complex organ in the human body. The regulation and 
maintenance of brain function requires high amounts of energy. The brain accounts for ~20% of 
total body energy consumption (25% of the glucose and 20% of the oxygen consumption), and 
brain energy levels are more resistant to starvation compared to other organs [279]. Glucose is 
considered the obligatory energy substrate in the adult brain requiring its continuous delivery 
across the blood brain barrier (BBB) (Figure 1.1); however, alternate energy sources can fuel 
brain function under energetic stress situations. For example, lactate transport across the BBB 
can provide ~8%–10% of the brain’s energy requirements and has been estimated to supply 
~20%–25% of energy at the expense of glucose consumption during energy demanding 
activities. Importantly the extracellular levels of lactate (0.5-1.5 mM) are similar to those of 
glucose, suggesting that an important pool of lactate is always available when required for 
consumption [209]. Ketone bodies derived from fatty acid metabolism in the liver can also cross 
the BBB [125].  
All brain regions are considered to be metabolically active with heterogeneity among structures. 
Remarkably, metabolic activity of the brain is constant over time. Brain metabolic activity 
consists of the oxidation of glucose to carbon dioxide and water (oxygen consumption), which 
results in the production of energy in the form of ATP. Importantly both oxygen consumption and 
glucose metabolism do not necessarily parallel each other. Glucose is delivered to brain cells 
through the blood and changes in brain glucose consumption are accompanied with vascular 
flow modifications.  An increase in blood flow of oxygen and glucose parallels an increase in 
brain activity. However, only glucose consumption (glycolysis) increases proportionately, while 
oxygen consumption (oxidative phosphorylation) does not, despite its increased supply [231, 
267]. Interestingly, only 10% of glucose yields lactate. In addition to the generation of energy, 
glucose metabolism in the brain is also important for the synthesis of carbohydrates for 
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glycoproteins and glycolipids, amino acids, one-carbon donors for methylation, and 
neurotransmitter precursors [231]. 
2.2. Cellular Composition of the Brain 
The brain tissue is made up of about 100 billion neurons and trillions of glia cells, and its 
bioenergetics and redox homeostasis is an integrated process between these different cell 
populations. Neurons are highly polarized cells with subcellular domains that serve different 
functions: the cell body (or soma), branching dendrites (signal receivers), and the axon that 
conducts nerve signals (Figure 1.2 and 1.5). Neuronal types and distribution are highly 
specialized across to the different brain regions. Specialization in both cytoarchitecture and 
neurotransmitter communication differentiates the function of neuronal populations [31, 304].  
Glial cells make up 90 percent of the brain's cells and regulate a number of physiological 
processes required for proper neuronal survival and function. Three types of glial cells exist in 
the CNS: oligodendrocytes, astrocytes, and microglia (Figure 1.3, 1.4 and 1.6). 
Oligodendrocytes are responsible for nerve fiber myelination, which provides axons with an 
“insulating coat” that enhances nerve impulse conduction. Oligodendrocytes have several 
processes and form several internodal segments of myelin on axons separated by gaps 
(Ranvier nodes) (Figure 1.4) [28, 299]. Astrocytes are small cells with processes arranged 
radially and a considerable molecular, structural, and functional diversity at the regional level. 
Astrocyte processes cover the external surface of capillaries in blood vessels (perivascular 
feet), the initial segment of most axons, and the bare segments of axons at the Ranvier nodes. 
Astrocytes processes cover a defined territory forming highly organized domains interconnected 
via gap junctions. They regulate neurotransmitter levels in the synaptic cleft, provide neurons 
with energetic and antioxidant precursors (Figure 1.3), play an important role in the migration of 
immature neurons, tissue repair, and regulate blood flow and inflammatory processes by 
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release of signaling mediators [301]. Microglial cells are resident macrophages distributed 
throughout the CNS that are embryologically unrelated to the other glial cells [44]. As innate 
immune cells, they are activated by infection, tissue injury (ischemia or trauma), or 
neurodegenerative processes. Upon activation, microglia cells retract their processes and 
migrate to the site of the lesion, where they proliferate and become antigen presenting cells. 
Microglia phagocyte degenerating cells and also act as sources of immunoregulatory and 
neuromodulatory factors such as cytokines, chemokines, neurotrophic factors. Microglia can be 
activated by cell-surface receptors for endotoxin, cytokines, chemokines, misfolded proteins, 
serum factors and ATP (Figure 1.6). While mild activation is a key adaptive immune response, 
continuous activation or overactivation of microglia is thought to contribute to neurodegeneration 
[97, 122, 123].  
The BBB refers to a barrier of capillaries that restrict the exchange of solutes between the blood 
and the brain extracellular fluid. Endothelial cells that form BBB capillaries are connected by gap 
junctions and regulate the exchange of metabolites and signaling molecules while preventing 
the entrance of deleterious molecules or agents to the brain (Figure 1.1) [261, 304]. 
2.3. Metabolic Specialization in Brain Cells 
Neurons are high energy consumers observing high rates of oxidative metabolism compared to 
glial cells. Neurons utilize most of their energy at the synapse to maintain and restore ionic 
gradients, and for the uptake and recycle of neurotransmitters (>80%).  Interestingly, neurons 
are thought to metabolize glucose primarily via the pentose phosphate pathway (PPP) to 
provide reducing equivalents required to maintain antioxidant defenses via the production of 
nicotinamide adenine dinucleotide phosphate (NADPH) (Figure 1.2 and 2.5) [39]. NADPH is 
also required for antioxidant defense in glial cells, but it can actually mediate ROS generation by 
NADPH-oxidases (NOXs) (Figure 3.1b). NADPH is a reducing agent as well, required for the 
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synthesis of lipids and nucleic acids and for the metabolism of neurotransmitters and aldehydes. 
Other mechanisms of generating NADPH exist, which include folate metabolism, NADP-malate 
dehydrogenase (malic enzyme), isocitrate dehydrogenase (IDH1 and 2) (Figure 2.6), glutamate 
dehydrogenase and nicotinamide nucleotide transhydrogenase (Nnt) (Figure 2.7). However, 
their contribution to NAPDH metabolism in neurons or glial cells has not been well defined [95]. 
In isolated brain mitochondria Nnt has been reported to be important in the removal of peroxides 
[202, 349].  
Neurons lack 6-phosphofructose-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) due to its 
continuous degradation by the ubiquitin-proteasome (UPS) pathway [9].  PFKFB3 is involved in 
the biogenesis and degradation of fructose-2,6-bisphosphate (F2,6BP), a glycolytic activator 
(Figure 2.2). In astrocytes, PFKFB3 is activated by AMPK (adenosine monophosphate-
activated protein kinase) and promotes glycolysis [131]. Because neurons have a limited 
capacity to upregulate glycolysis in response to stress, they depend on the shuttle of lactate 
from astrocytes and oligodendrocytes as fuel for mitochondrial OXPHOS (oxidative 
phosphorylation) (Figure 1.3 and 1.4) [32, 102, 183, 237].  Neuronal function ex vivo can be 
maintained by lactate in the absence of glucose [96]. To date, the primary neuronal energy 
substrate (glucose vs lactate) and the relative contributions of glycolysis and OXPHOS to 
neuronal bioenergetics (ATP) are still under debate [85, 142, 258, 290]. However, the fact that 
mice with a decreased expression of the neuron-specific glucose transporter GLUT3 do not 
observe alterations in glucose utilization, while astrocytes-specific GLUT1 deficiency results in a 
severe neurological phenotype supports the idea of the preferential consumption of glucose by 
astrocytes and the astrocytes-neuron lactate shuttle hypothesis (Figure 1.1) [308, 331].  
Even though glial cells and neurons have the same oxidative capacity, glial cells are highly 
glycolytic and a large portion of glucose metabolism is directed to lactate production and its 
release to the extracellular space. Astrocyte glucose consumption does not match their energy 
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expenditure, which only accounts for 5-15% of the glucose consumed by the brain. Recent 
studies have demonstrated that the activity of pyruvate dehydrogenase (PDH), which 
determines the entry of pyruvate into the tricarboxylic acid (TCA or Krebs) cycle (Figure 1.3), is 
reduced by its phosphorylation in astrocytes [360]. Glucose storage within brain cells is found in 
astrocytes in the form of glycogen, which can also be broken down to lactate, but some 
evidence exist for the generation of glucose via glucogenesis [231]. In addition, glutamate can 
be used as a carbon source for the TCA cycle in both neurons and astrocytes, while acetate is 
preferentially used by astrocytes [32, 150, 208, 306] .  The creatine / phosphocreatine / creatine 
kinase system has also been proposed to contribute to the regeneration of ATP in brain [30]. 
Ketone bodies (3-β-hydroxybutyrate [3BHM], acetoacetate, and acetone) and free fatty acids 
(and lactate) can be transported across the BBB during starvation and are thought to provide 
two thirds of the total energy required for the brain. Neurons very poorly metabolize hydrogen-
rich free fatty acids (FFA) to obtain energy (Figure 2.12), which has been related to the high O2 
demand and resultant generation of superoxide anion (O2
•-) from β-oxidation [287]. However, 20 
% of total adult brain energy comes from FFA oxidation, mostly in astrocytes.  Astrocytes can 
oxidize FFA (Figure 1.3) and ketone bodies, while neurons and oligodendrocytes can only use 
ketone bodies. β-oxidation of fatty acids by astrocytes provides ketone bodies for neurons as 
well [138, 287].  
Astrocytes are important players in the regulation of neuronal excitability by the removal of 
released neurotransmitters. The excitatory amino acid glutamate (Glu) is taken up by the Na+-
dependent excitatory amino acid transporter-1 (EAAT1 or GLAST) and EAAT2 (GLT-1) and 
converted to glutamine (Gln) by the astrocyte-specific enzyme glutamine synthetase (GS) 
(Figure 1.3 and 2.10). Glutamine is exported and transferred to neurons (glutamate-glutamine 
cycle) to regenerate glutamine via glutaminase (GLS) activity (Figure 1.2 and 2.10). Glutamate 
can also be utilized for de novo synthesis of the antioxidant glutathione (GSH) (Figure 1.3, 1.5, 
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2.11 and 3.4b) [32, 288].  In general, neurons have limited defense mechanisms against ROS 
when compared to astrocytes (Figure 1.2 and 1.3). Astrocytes contain higher levels of 
endogenous antioxidants and antioxidant systems being more resistant to oxidative stress, 
which is explained by the activation of the antioxidant response via the nuclear factor erythroid-
2-related factor 2 (Nrf2) transcription factor (Figure 1.3 and 3.7) [293]. While several reports 
demonstrate that Nrf2 signaling can be induced by oxidative stress in neurons [120], it has been 
recently suggested that neuronal Nrf2 is epigenetically silenced [33], and that induction of the 
Nrf2 pathway does not seem to restore their antioxidant protection  (Figure 1.5) [152]. 
Astrocytes also have higher levels of NADPH and G6PD (glucose-6-phosphate dehydrogenase) 
[105]. Interestingly, antioxidant genes in neurons are transcriptionally regulated independent of 
Nrf2 by synaptic activity through the activating transcription factor 4 (ATF4) and the activator 
protein 1 (AP-1) (Figure 1.5) [29, 189]. Both neurons and astrocytes can synthesize GSH, but 
neurons depend on the supply of GSH precursors (Figure 1.3 and 1.5). GSH is released from 
astrocytes via the ATP-binding cassette transporters subfamily C member 1 transporter 
(ABCC1, or multidrug-resistance-associated protein 1 [MRP1]) [133]. Extracellular GSH is then 
degraded by the γ-glutamyl transpeptidase (γGT) to produce l-cysteine-l-glycine (CysGly), which 
is cleaved further by the neuronal aminopeptidase N (ApN) into the amino acids glycine and 
cysteine that are taken up by neurons for GSH synthesis (Figure 1.5) [19, 32]. Thus, both the 
glutamate-glutamine cycle and the GSH export are also involved in the regulation of the 
neuronal redox environment by astrocytes. 
During inflammation, changes in central carbon metabolism have been recently demonstrated to 
contribute to the activation and survival of astrocytes and microglia. Activation of astrocytes 
increases the generation of ROS, but themselves are largely resistant to these high ROS levels. 
Interestingly, glucose deprivation impairs GSH metabolism in astrocytes and their survival upon 
activation [65]. Inflammation also alters mitochondrial dynamics by favoring mitochondrial fission 
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over fusion in astrocytes via autophagy [238].Upon injury, exposure to pro-inflammatory signals, 
or chemicals/xenobiotics microglia become polarized to a pro-inflammatory M1 phenotype 
triggering the production of pro‐inflammatory cytokines and the upregulation of ROS production. 
The M1 phenotype of microglia is considered an adaptive immune response that was recently 
reported to be paralleled by a switch in their metabolism from oxidative phosphorylation to 
glycolysis that also enhances carbon flux to the PPP (Figure 1.6) [110, 249, 329]. An alternative 
activation state defined as M2 (with different subclasses) is characterized by the release of anti-
inflammatory factors to re-establish cell homeostasis. Interestingly, M2 upon activation of 
microglia with interleukin (IL)-4/IL13, no changes in mitochondrial oxygen consumption or 
lactate production were evidenced by extracellular flux analysis [249]. A comparative study 
demonstrated that astrocytes are more resistant to oxidative damage than microglia or 
oligodendrocytes [135]. 
3. Parkinson’s Disease 
PD is the second most common neurodegenerative disorder affecting ~6 million people 
worldwide. PD is characterized by the progressive and selective loss of the dopaminergic (A9) 
neurons in the SNpc that conveys motor dysfunction. Although neuronal cell death is a cardinal 
feature of PD, the mechanisms and pathways involved remain unclear, mainly because in the 
majority of cases the cause of PD is unknown. The major risk factor identified for PD is aging as 
its prevalence and incidence increases exponentially from ages 65 to 90. A fraction of PD 
occurrence is also directly related to mutations in genes such as those encoding α-synuclein 
(SNCA), DJ-1 (PARK7), PTEN-induced putative kinase 1 (PINK1), leucine rich repeat kinase 2 
(LRRK2) and Parkin (PARK2), while other genetic modifications only increase the risk of 
developing this condition.. Over 90% of PD occurs in a sporadic (idiopathic) form from which 
only 5% of those cases are linked to de novo genetic alterations (SNCA and LRRK2) [165]. 
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Thus, PD occurs most commonly without a clearly defined genetic basis. While the etiology of 
PD has not been clearly established, epidemiological data suggests that exposure to 
environmental / occupational agents might play a key role in this disorder [112].  Thus, it is now 
thought that PD arises as a syndrome from the convergence of genetic susceptibility, 
environmental exposures, and aging. At the molecular level, PD risk factors have been shown to 
trigger neurodegeneration by mitochondrial dysfunction, oxidative stress, and abnormal protein 
accumulation [188, 347], but the exact mechanisms are still unclear. 
In addition to neurons, the function of other brain cells is altered in PD, which is also reported to 
contribute to the degeneration of dopaminergic neurons. Since  astrocytes contribute to both 
energy and antioxidant homeostasis in neurons it is likely that dopaminergic neurons are more 
susceptible to oxidative stress and energy failure due to the low number of astrocytes in the 
SNpc compared to other brain areas. [228]. Neurotrophic factors released by astrocytes such as 
the mesencephalic astrocyte-derived neurotrophic factor (MANF), the glial cell line-derived 
neurotrophic factor (GDNF), and the brain-derived neurotrophic factor (BDNF) regulate neuronal 
bioenergetics (Figure 2.1), and are also thought to contribute to the survival of dopaminergic 
neurons [213]. While astrocytes normally serve a neuroprotective role, reactive astrocytes are 
found in PD brains and are considered to contribute to neuroinflammatory processes [57, 330].  
The density of microglial cells is higher in the SN compared to other brain regions. Increased 
levels of activated microglia and pro-inflammatory cytokines (IL-1β, tumor necrosis-factor  
[TNF], IL-2 and IL-6) have been found in the SNpc of elderly individuals. Furthermore, 
activation of microglia in PD brains has been proposed to be triggered by aggregates / fibrils of 
-synuclein, environmental toxicants, infectious events, and ATP and/or signaling proteins 
released from neurons (Figure 1.6) [163, 200, 274, 359]. PD-related genes PARK7, PINK1 and 
LRRK2 have also been reported to modulate mitochondrial dysfunction, oxidative stress and the 
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inflammatory response of glial cells [63, 234, 239, 240, 280]. Besides microglia, infiltrating cells 
such as T-lymphocytes, and neutrophiles have been reported to contribute to inflammation in 
neurodegenerative disorders including PD [115, 147, 276]. For example, pathogenic T-cell 
populations potentiate microglial activation [41, 275]. Importantly, peripheral cells such as 
lymphocytes and neutrophiles from PD patients observe mitochondrial dysfunction and 
increased oxidative stress [18, 55, 107, 263, 264, 326], but whether ROS generation from 
infiltrating cells contributes to PD has not been explored. A disruption in the BBB has also been 
linked to aging and PD, which might involve dysfunction in both endothelial and astrocytes [45, 
117]. Breakdown of the BBB leads to a dysregulation in ionic transport and xenobiotic/toxin 
clearance, and the initiation of an inflammatory response that contributes to neuronal 
dysfunction and neurodegeneration [247]. 
3.1. Mitochondrial Dysfunction in Parkinson’s Disease 
3.1.1. Genetics and Complex I Dysfunction 
Mitochondrial dysfunction is a common trait for many human disorders including 
neurodegeneration. The central role of mitochondrial dysfunction was recognized very early in 
the PD field. A decrease in the activity of the mitochondrial electron transport chain (ETC), 
primarily Complex I, is found in the SNpc of patients with PD (Figure 2.9 and 3.1a) [129, 160, 
283, 285]. Mitochondrial DNA (mtDNA) mutations have also been discovered in rare families 
exhibiting parkinsonism. Somatic (acquired) point mutations and deletions in mtDNA also 
accumulate with age in the SNpc, but no specific mutations responsible for mitochondrial 
dysfunction in PD have been identified [70]. Mutations in polymerase gamma (POLG) are linked 
to mitochondrial defects in Complex I and IV acquired in PD [271]. Accordingly,  a high 
frequency of mitochondrial Complex I mutations was found in PD patients [298]. Gene variations 
in the mitochondrial transcription factor A (TFAM) that controls mtDNA have also been 
associated with PD [10]. 
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Mitochondrial dysfunction in PD has been linked to oxidative stress, as electron leakage from its 
metabolism is the primary source for ROS formation (Figure 3.1a).  PD-associated genes have 
been shown to alter mitochondrial function and homeostasis leading to increased ROS 
formation [317]. Accumulation of α-synuclein has been suggested to trigger mitochondrial 
oxidative stress [83]. DJ-1, PINK1 and Parkin deficiency or mutations impair mitochondrial 
respiration and render cells more susceptible to oxidative stress and mitochondrial dysfunction 
(Figure 2.9 and 4)  [4, 13, 149, 236, 254, 310]. Phosphorylation of the Complex I subunit 
NdufA10 by PINK1 is necessary for ubiquinone reduction (Figure 2.9) [235]. Gain-of-function of 
LRRK2 mutations disturb mitochondrial bioenergetics and mitochondrial dynamics leading to 
increased ROS formation [246, 256]. In the mitochondria, O2
•- is generated in the matrix by 
electron leakage from Complex I [118], and in both the matrix and the inner membrane space 
(IMS) by electron leakage from Complex III (Figure 3.1a) [58]. In vitro and in vivo, dopaminergic 
neurons are highly sensitive to Complex I inhibitors whose toxicity is ascribed, at least partially, 
to the generation of ROS [27, 173, 216, 278, 343].  Other environmental agents linked to PD or 
dopaminergic toxins have also been shown to primarily mediate dopaminergic cell death via 
mitochondrial dysfunction [50, 111, 278]. 
3.1.2. Bioenergetics 
While mitochondrial dysfunction in PD is thought to mediate the increased generation of ROS 
and subsequent oxidative damage, another major consequence is energy failure linked to the 
inability of neurons to compensate their lack of capacity to generate ATP. Very few studies have 
aimed at understanding and distinguishing between the contribution of both oxidative stress and 
energy failure in dopaminergic cell death associated with mitochondrial dysfunction.  A number 
of studies have shown that antioxidants protect dopaminergic cells from the toxicity of Complex I 
inhibitors [26, 159, 167, 191, 266]. However, we and others have clearly demonstrated that 
dopaminergic cell death induced by Complex I inhibition cannot be directly linked to the 
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generation of ROS or completely prevented (if at all) by antioxidants [47, 49, 100, 171, 178, 217, 
241, 278, 282, 355]. This might explain the failure of antioxidants (particularly mitochondria 
targeted antioxidants) in PD therapy [1, 300], despite their reported success in preclinical 
models [108, 302]. Furthermore, some studies suggest that impaired mitochondrial 
bioenergetics might be the main cause for neuronal cell death induced by Complex I inhibitors 
rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, or its active analog 1-
methyl-4-phenylpyridinium [MPP+])  [27, 86, 343]. Supplementation of cells with Coenzyme Q10 
(ubiquinone), an electron carrier in the ETC, protects against the toxicity of Complex I inhibitors 
that block the electron flow from NADH dehydrogenase to Coenzyme Q [2]. Similarly, directly 
delivery of electrons from NADH to cytochrome c using methylene blue attenuates 
dopaminergic neurodegeneration induced by rotenone [345]. Importantly, because a 50% 
inhibition of Complex I is required to cause significant ATP depletion, and Complex I activity is 
only reduced by 25–30% in PD, ATP depletion might as well not be the single causative event 
for dopaminergic neurodegeneration [77, 284]. 
Dopaminergic SNpc neurons are particularly susceptible to energy failure since they consume a 
significant amount of energy during their pacemaking activity to maintain a basal dopamine (DA) 
tone in innervated regions (striatum). This level of activity and energy consumption also leads to 
increased levels of basal oxidative stress [121].  In addition, their extended (and probably 
unmyelinated) axon, and the number of striatal synapses established are characteristics 
expected to exert a high energy demand on the maintenance of plasma membrane potential 
(ionic gradients), protein/organelle (mitochondria) traffic and homeostasis [218, 253, 262]. 
Importantly, the intrinsic bioenergetic capacity between dopaminergic and non-dopaminergic 
presynaptic synaptosomes do not differ [66], suggesting that other factors besides energy 
dysfunction contribute to the loss of dopaminergic cells. Energy failure in dopaminergic cells 
would be expected to siphon energy from other important ATP-dependent homeostatic 
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processes in an attempt to maintain their excitability (including active uptake of 
neurotransmitters into vesicles) and function. These processes include: 1) protein quality control 
mechanisms (autophagy and the UPS) whose failure leads to the accumulation of misfolded / 
oxidized protein aggregates  (Figure 1.2) [73]; 2) transport of mitochondria to pre-synaptic and 
post-synaptic sites (kinesin motors require ATP) (Figure 4.6) [68]; and 3) mitochondrial 
biogenesis and dynamics (fusion, fission and mitophagy) (Figure 1.2 and 4)[221]. In addition, 
energy depletion is expected to impair the ATP-dependent proton pump that drives vesicular 
accumulation of DA augmenting its cytosolic levels and oxidative stress as a consequence 
(Figure 1.2) [17, 203, 204]. Glutamatergic afferents in the SNpc suggest that energy impairment 
in astrocytes and neurons might also contribute to dopaminergic cell death due to an impaired 
uptake of extracellular glutamate that leads to excitotoxic cell death, but this hypothesis requires 
further experimental support [12, 224, 343]. 
While neurons have a limited capability to upregulate glycolysis, an increase in glycolysis 
counteracts energy failure and dopaminergic cell death induced by mitochondrial 
dysfunction.[54, 136, 174]. Alternative energy sources have also been demonstrated to protect 
against PD neurodegeneration. Under energy deprivation, ADP phosphorylation by creatine 
kinase (CK) to ATP requires phosphocreatine for the donation of the phosphoryl group. The 
phosphocreatine pool is maintained / regenerated from creatine and ATP under normal 
conditions by both the cytosolic and the mitochondrial forms of creatine kinase. Creatine 
supplementation has been shown to protect against MPTP toxicity [16, 219]. However, in clinical 
trials creatine supplementation does not slow down the progression of PD [161]. Conversely, 
the administration of ketone bodies (D-beta-hydroxybutyrate) bypasses the Complex I blockade 
by MPTP and reduce dopaminergic neurodegeneration by entering the mitochondrial ETC 
directly at Complex II.   [314]. Accordingly, a ketogenic diet has been reported to exert 
protective effects in PD [323]. 
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3.1.3. Mitochondrial dynamics 
Mitochondrial dysfunction in PD has also been linked to the indirect alteration of mitochondrial 
dynamics (fusion and fission, turnover, biogenesis, and transport) that is involved in the 
regulation of mitochondrial health, mass and subcellular location in response to stress (Figure 
4) [94, 322]. We will next discuss these processes in the context of how they regulate both 
bioenergetics and redox homeostasis in PD.  
Mitochondria are dynamic organelles that undergo continuous events of biogenesis, remodeling 
and turnover. Fusion and fission are opposing processes working in concert to maintain the 
shape, size, number of mitochondria and their physiological function. Fusion enables content to 
be mixed between neighboring mitochondria and has been proposed to rescue “moderately” 
dysfunctional mitochondria. Fusion is mediated by the initial oligomerization of dynamin 
GTPases mitofusins 1 and 2 (Mfns) at the outer membrane to tether adjacent mitochondria 
together, and the subsequent fusion of the inner membranes by the optic atrophy GTPase Opa1 
(Figure 4.1). Fission represents a quality control mechanism to transform damaged elongated 
mitochondria into a form suitable for engulfment by mitochondrial autophagy or mitophagy, and 
has also been proposed to modulate mitochondrial axonal transport. Fission requires 
recruitment of the GTPase Drp1 (dynamin-related protein 1) via mitochondrial surface receptors 
(mitochondrial fission 1 protein [Fis1], mitochondrial fission factor [Mff] and mitochondrial 
dynamics proteins 49 and 51 [MiD49, MiD51]) for the assembly of the fission machinery 
subsequently leading to membrane scission (Figure 4.2) [259]. Complex I inhibition promotes 
Drp1-mediated fission and mitophagy. Conversely, inhibition of fission protects against 
dopaminergic cell death induced by Complex I inhibitors [322]. Importantly, recent evidence 
indicates that alterations in mitochondrial dynamics by PINK1 deficiency are a result of impaired 
bioenergetics [325]. Mitophagy has been shown to be regulated by PINK1 and the translocation 
of Parkin from the cytoplasm to “defective” mitochondria (Figure 4.3).  Fusion arrest by 
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polyubiquitination and proteasomal degradation of mitofusins (Mfn1 and Mfn2) by Parkin is 
required for mitophagy (Figure 4.4). On the other hand, polyubiquitination of the voltage-
dependent anion channel 1 (VDAC1) by Parkin recruits the ubiquitin binding protein p62 that 
also interacts with the autophagosomal protein LC3/GABARAP (Figure 4.3). Loss of the E3-
ubiquitin ligase Parkin and PINK1 has been shown to promote Drp1-dependent fission, loss of 
mitochondrial membrane potential, and energy failure [207]. Contradictory results exist 
regarding the role of  Parkin on promoting proteasomal degradation of the fission promoting 
proteins Drp1 and Fis1, but if corroborated, they would suggest a complex scenario where 
Parkin can regulate both mitochondrial fusion and fission events depending on the degree of 
mitochondrial stress [94]. Importantly, recent reports have demonstrated that only prolonged 
(chronic) mitochondrial depolarization induces Parkin translocation or mitophagy in neurons 
(Figure 4.2) [180, 321]. Furthermore, mitophagy induced by dysfunction in mitochondrial 
respiration is independent from Parkin in dopaminergic neurons [305]. These results suggest 
that disruption in mitophagy is not the primary cause for PD linked to Parkin mutations. 
Supportive of this hypothesis is the observation that Parkin and PINK1 have also been 
demonstrated to mediate the formation of mitochondria-derived vesicles for the degradation of 
oxidized and damaged proteins via the lysosome (Figure 4.5) [223]. 
Other PD related genes also affect mitochondrial dynamics. -synuclein has also been shown to 
impair mitochondrial fusion, which seems to precede mitochondrial dysfunction [242], while the 
A53T mutant was reported to stimulate mitophagy [67]. Loss of DJ-1 function promotes 
mitochondrial fission and mitophagy, but mitochondrial alterations are prevented by PINK1 and 
parkin [141, 313].  A pathogenic increase in the activity of LRRK2 also promotes fission [333]. 
Activation of AMPK by starvation promotes mitophagy, but its role in PD has not been clearly 
elucidated [92].  
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Mitochondria are actively transported into axonal and dedritic terminations due to the high 
energy requirements for synaptic neurotransmission (Figure 4.6). Notably, dopaminergic axons 
have reduced mitochondrial numbers compared to other synaptic terminals. Complex I inhibitors 
and PD-related genes impair mitochondrial transport, which leads to energy depletion in 
synaptic terminals and dopaminergic axons that already have reduced mitochondrial numbers 
compared to other terminals [162, 190]. PINK1 and Parkin also regulate mitochondrial 
movement via phosphorylation, ubiquitination and degradation of Miro that disrupts its 
interaction with the adapter protein Milton and the kinesin motor protein KIF5a. The loss of this 
interaction between Miro and Milton/KIF5a leads to the detachment of mitochondria from 
microtubules (Figure 4.6) [199, 332]. Finally, Parkin has also been shown to induce the 
proteasomal degradation of the parkin-interacting substrate (PARIS), a transcriptional repressor 
of the peroxisome proliferator-activated receptor gamma-co-activator 1-alpha (PGC-1α), which 
stimulates mitochondrial biogenesis (Figure 4.7) [294]. 
Similar to neurons, alterations in mitochondrial function and quality control are also expected to 
occur in glial cells affected by PD risk factors. However, other than its involvement in the 
activation of inflammatory processes and increased ROS formation (mentioned in the next 
section), the pathological consequences that glial mitochondrial dysfunction has in PD is 
unclear. Astrocytes have the same oxidative capacity as neurons, but their energy requirements 
are met through glycolysis, and they are resistant to mitochondrial toxins. The physiological 
importance of mitochondrial oxidative metabolism in glial cells is still obscure. Astrocytes 
derived from Parkin knockout and transgenic mutant -synuclein exhibit mitochondrial functional 
and morphological defects, which translate into the impairment of their neurotrophic effects in 
neuronal differentiation [286].  DJ-1 knockout in astrocytes alters mitochondrial function and 
impairs neuroprotection against Complex I inhibition [175]. There is no evidence that glial cells 
degenerate (or die) in PD. Interestingly, impaired astrocyte proliferation (astrogliosis) has been 
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reported in PD brains and this phenomenon correlates inversely with α-synuclein accumulation 
[315]. Accordingly, PINK1 knockout astrocytes exhibit defective proliferative signals, which were 
linked to alterations mitochondrial metabolism [63]. Recently, damaged mitochondria have been 
reported to be transferred from neuronal axons for their turnover in astrocytes [78], and 
conversely, astrocytes have been shown to transfer mitochondria to promote neuronal survival 
[127]. Thus, it is plausible that when transferred, defective mitochondria from astrocytes can 
have deleterious effects in neuronal function during PD. 
3.2. Oxidative Stress and Alterations in Redox Metabolism 
3.2.1. Generation of Reactive Oxygen Species and Oxidative Damage 
In addition to the role of mitochondria as the primary source for O2
•-, other important alterations 
in redox balance contribute to dopaminergic dysfunction. Several other organelles are important 
sources for ROS as well, and under certain circumstances, might actually play a bigger role 
than mitochondria in ROS generation [42]. ROS are produced in the endoplasmic reticulum 
(ER) as a consequence of the activity of oxidoreductases that catalyze disulfide bond formation 
in nascent proteins. Protein disulfide isomerase (PDI) accepts electrons from cysteine thiol 
residues leading to the formation of protein disulfide bonds. ERO1 (ER oxidoreduction) transfers 
electrons from PDI to O2, which results in the production of H2O2  (hydrogen peroxide) [311]. ER 
stress and the activation of the unfolded protein response (UPR) have been reported in PD; 
however, its causative role in oxidative damage has not been established [230].  
Another important source of O2
•- is the NOX family of enzymes that catalyze the production of 
O2
•- from O2 and NADPH (Figure 3.1b) [139]. Distinct isoforms of NOX enzymes have been 
reported in different brain regions, but their activation appears to be primarily restricted to glial 
cells as a response to environmental exposures or inflammatory agents [103]. NOX-derived 
ROS from glial cells has been shown to contribute to oxidative damage and dopaminergic 
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neurodegeneration (Figure 1.6) [139, 309]. Nitric oxide (•NO) is generated from L-arginine by 
nitric oxide synthases (NOS) which also requires reducing equivalents from NADPH [233]. 
When O2
•- reacts with •NO it generates peroxynitrite (ONOO-) (Figure 3.1a) [82]. Inducible NOS 
(iNOS) is also activated by mitochondrial toxins and inflammatory events in microglia at the 
substantia nigra to promote neurodegeneration (Figure 1.6) [20, 194]. Neuronal NOS (nNOS) 
also contributes to dopaminergic cell death induced by MPTP [124, 265]. In addition, NOS 
uncoupling by the PD-related pesticide paraquat has also been recognized as an important 
source for O2
•- [206, 212].  
O2
•- can be dismutated in via enzymatic (via O2
•- dismutases [SODs]) or non-enzymatic reactions 
to H2O2 (Figure 3.1a and 3.1b). SOD activity was found to be increased in post-mortem PD 
brains [51, 281]. Metals such as iron (Fe) can also promote ROS formation via the 
Fenton/Haber-Weiss reaction that catalyzes the formation of hydroxyl radical (•OH) by their 
reaction with H2O2 (Figure 3.2).  In the brain, Fe is most abundant in SNpc dopaminergic 
neurons. Increased Fe deposition and increased free Fe concentrations have been found in the 
SNpc of PD brains, which may lead to increased generation of •OH [295]. In PD, Fe is deposited 
abundantly in the neuromelanin (NM) granules of SNpc dopaminergic neurons [295]. Fe 
deposition in PD might be related to alterations in Fe transport and storage systems [90, 134, 
154, 177]. •OH formation by Fe has also been proposed to involve α-synuclein (Figure 3.2) [61, 
214, 251, 320]. Because of their high Fe content, lysosomes are another important potential 
source of ROS [170], and lysosomal breakdown has also been linked to PD pathogenesis [81]. 
Finally, disruption of Fe-Sulfur (S) clusters by oxidative stress induced by paraquat or PINK1 
mutants has also been proposed to enhance oxidative damage (Figure 3.2) [46, 93]. 
Oxidative stress in PD is also associated with the pro-oxidant properties of dopamine. Mutant α-
synuclein down-regulates the vesicular monoamine transporter (VMAT2) [203, 204]. In the 
cytosol, dopamine is either metabolized by monoamine oxidase (MAO) to generate H2O2, or 
24 
 
auto-oxidized in the presence of Fe generating O2
•-, H2O2 and dopamine-quinone species (DAQ) 
(Figure 3.5) [3]. Dopaminergic cell death induced by mitochondrial toxins has been proposed to 
depend on dopamine oxidation [158, 197]. DAQ byproducts from DA oxidation have been 
reported to react with protein cysteine thiols [126], and with glutathione (GSH) to form adducts 
(GS-DAQ) by the activity of GSH-S-transferases (GSTs) [75, 291]. GSTs are also involved in 
the detoxification of GSH adducts with byproducts of lipid peroxidation such as 4-
hydroxynonenal (4-HNE) which has been shown to generate toxic protein adducts in PD 
(Figure 3.4b) [352].  
3.2.2. Antioxidant Defenses 
Oxidative stress is counteracted by cellular antioxidant mechanisms.  A number of scavenging 
mechanisms exist against H2O2. Catalase mediates the decomposition of H2O2 and is primarily 
localized in the peroxisomes (Figure 3.3).The activity of catalase was reported to be reduced in 
the SN and putamen of PD brains [11].  Peroxiredoxins (Prxs) are thiol peroxidases primarily 
seen as regulators of peroxide signaling [74]. Except for Prx6, which depends on the reducing 
power of GSH, thioredoxins (Trx) provide the reducing equivalents required for the peroxide 
scavenging activity of Prxs.  The Trx redox system itself depends on thiol-disulfide exchange 
reactions at the active site, and Trx reductase (TrxR) transfers reducing equivalents from 
NADPH to reduce Trxs (Figure 3.3). Overexpression of Prx1, Prx2 and Prx4 protects against 6-
hydroxydopamine (6-OHDA)-induced dopaminergic cell death [137, 184], whereas silencing 
mitochondrial Prx3 and Prx5 increases sensitivity to MPP+ [80]. The Trx/TrxR system also 
protects against MPP+- 6-OHDA- and paraquat-induced toxicity in dopaminergic cells [21, 23, 
201, 346].  
A decrease in the levels of GSH is one of the earliest biochemical alterations associated with 
PD as demonstrated by the observation that GSH loss occurs in incidental Lewy body disease, 
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which is considered an asymptomatic precursor to PD [146, 260, 296]. Accordingly, inducible 
depletion of GSH promotes nigrostriatal degeneration in mouse [62]. GSH peroxidases (GPx) 
and Prx6 use the reducing power of GSH to hydrolyze peroxides generating GSH disulfide 
(GSSG) as a byproduct (Figure 3.4a).  Mice deficient in GPx1 exhibit an increased sensitivity to 
MPTP toxicity [166], while its overexpression protects against MPP+- and 6-OHDA-induced 
toxicity in vitro and in vivo [35, 157, 277, 312]. GSH-dependent Prx6 was recently shown to 
exacerbate dopaminergic neurodegeneration induced by MPTP, but this effect was linked to its 
calcium-independent phospholipase A2 activity and increased 4-HNE levels [354].GSH 
reductase (GR), which recycles GSSG back to GSH, requires NADPH as the electron donor 
reluctant, and the pentose phosphate pathway enzyme glucose-6-phosphate dehydrogenase 
(G6PD), is indispensable for the regeneration of NADPH from NADP+ (Figure 2.5 and 3.4a). 
Downregulation of PPP enzymes and a failure to increase the antioxidant reserve capacity are 
early events in the pathogenesis of sporadic PD [89]. Transgenic mice overexpressing G6PD in 
dopaminergic cells are resistant to MPTP-induced toxicity [227]. Impairment in the PPP leads to 
the depletion of NADPH and dysfunction in the GSH/Grx, Prx/Trx/TrxR and catalase systems, 
as well as the decrease in purine synthesis via ribose 5-phoshate [349]. We have recently 
demonstrated that the PD-related pesticide paraquat hijacks the NADPH from the PPP for its 
redox cycling, promoting oxidative stress and a toxic synergism when combined with -
synuclein overexpression [14, 186]. NOX and NO-mediated formation of ROS and reactive 
nitrogen species is also expected to be directly associated with NADPH levels. In contrast 
G6PD and IDH1 exert a protective effect against the toxicity of MPTP/MPP+ [227, 344]. These 
observations might explain why there is no generalized association between changes in G6PD 
activity and PD [104]. 
Glial cells also regulate antioxidant defenses in neuronal cells. Recently, the role of astrocytes 
in the protection of neurons against oxidative stress was elegantly demonstrated. Conditional 
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depletion of astrocytes was observed to promote neuronal injury by oxidative stress [289]. 
Accordingly, transcriptional regulation of antioxidant systems via the nuclear factor (erythroid-
derived 2)-like 2 (Nrf-2) in astrocytes prevents dopaminergic cell death induced by MPTP [56]. 
3.2.3. Bioenergetics and Redox Balance 
Alterations in the bioenergetics of dopaminergic cells also have an impact on antioxidant 
systems. Energy is required for a number of antioxidant systems to work. GSH (l-γ-glutamyl-L-
cysteinyl-glycine) synthesis is initiated by generation of γ-glutamylcysteine from glutamate and 
cysteine via the glutamate-cysteine ligase (GCL), and the subsequent addition of glycine by the 
activity of GSH synthetase (GSS) (Figure 1.3and 3.4b) [101, 226, 297]. Both reactions requiring 
ATP consumption. The transsulfuration pathway (Figure 2.11) contributes to the generation of 
cysteine, the rate limiting substrate for GSH synthesis, from one carbon metabolism of serine → 
cystathionine → cysteine. Interestingly, high levels of homocysteine, a co-substrate with serine 
for cystathionine formation, have been found in PD brains [36]. Both glycine and glutamate are 
also byproducts of central carbon metabolism (glycolysis or TCA cycle, respectively) (Figure 
2.10 and 2.11). However, the contribution of their biosynthetic pathways to redox balance in 
neuro-glial cells is unclear. Efflux of GSH-adducts (including those of DA and 4-HNE) is ATP-
dependent as well. Thus, GSH-dependent antioxidant systems and detoxification pathways are 
expected to be impaired by energy failure associated with mitochondrial dysfunction (Figure 
3.4b) [72].  The reduction of hyperoxidized Prxs (sulfenylated, SO2H) by sulfiredoxin (Srx) relies 
on the initial formation of a sulfinic phosphoryl ester (Cys-SPO2PO3
2-) between the Srx and Prx 
that requires ATP consumption (Figure 3.3) [38]. ATP is also required for the synthesis of 
NADP+ via NAD+ kinase (Figure 3.8). Transcriptional regulation of antioxidant defenses (SOD1 
[CuZnSOD], SOD2 [MnSOD], the modifier and catalycic GCL subunits [GCLM and GCLC], and 
GSTs) via Nrf2 and conversely, the ubiquitination and degradation of the Nrf2-kelch-like ECH-
associated protein 1 (Keap1) cytosolic complex also require energy (Figure 3.7)  [155].  ATP 
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depletion is also anticipated to impair oxidative DNA-damage repair systems (Figure 3.7) [76, 
119, 307, 336]. GCLM knockout was shown to increase dopaminergic neurodegeneration 
induced by paraquat [192] and recently, it was also reported that GSH depletion in GCLM 
knockout astrocytes induces a depletion in glycogen levels demonstrating a link between redox 
balance and bioenergetics/central carbon metabolism [176]. 
3.3. Alterations in Central Carbon Metabolism 
3.3.1. Glucose Metabolism and Glycolysis 
In addition to the energy failure linked to mitochondrial dysfunction, alterations in central carbon 
metabolism have also been reported to occur in PD. A decrease in glucose metabolism and 
abnormal elevated levels of lactate / pyruvate have been observed in PD patients [5, 91, 130, 
255]. Disruption of glycolysis in astrocytes and oligodendrocytes triggers axon damage and 
neurodegeneration [182, 328]. Interestingly, glucose deprivation promotes -synuclein 
aggregation (Figure 1.2) [34]. In contrast, lactate has been reported to exert an opposite effect 
on -synuclein [151]. We and others have demonstrated that glycolysis is upregulated in 
response to mitochondrial dysfunction, and that ATP generation via glycolysis exerts a 
protective role against Complex I inhibition [14, 22, 52-54, 220, 337, 351], As mentioned before, 
failure of neuronal cells to upregulate this pathway seems to make them rather sensitive to 
mitochondrial dysfunction [132]. Interestingly, dietary restriction and administration of 2-deoxy-d-
glucose exerted protective effects against MPTP toxicity [87]. We have recently found that 
paraquat inhibits glucose metabolism and upregulates carbon flux via the PPP to increase its 
redox cycling by hijacking reducing equivalents from NADPH [186]. This effect was paralleled by 
an impairment of NADPH-dependent antioxidant systems leading to GSH depletion and Prx 
hyperoxidation [278].  Inhibition of glycolysis by paraquat, was likely associated with the 
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inhibition of phosphofructokinase (PFK) by citrate whose accumulation is linked to the inhibition 
of aconitase by PQ-derived ROS (Figure 2.2 and 2.8)   [46, 106, 186, 243]. 
PD-related genes SNCA (-synuclein),  PARK2 (Parkin), PINK1 and PARK7 ( DJ-1) have been 
reported to indirectly regulate glycolysis by modulation of different signaling proteins including 
p53, the hypoxia-inducible factor 1-alpha (HIF-1) (Figure 2.10)  and the adenosine 
monophosphate-activated protein kinase (AMPK) [272, 273, 292, 356]. Alterations in cellular 
energy are tightly monitored by the master regulator of metabolism AMPK [48]. We have 
recently demonstrated that AMPK signaling protects against paraquat-induced dopaminergic 
cell death and that this effect is independent from glucose metabolism and likely linked to the 
regulation of mitochondrial bioenergetics (Figure 4.7) [14]. Accordingly, a protective role for 
AMPK against mitochondrial dysfunction and toxicity induced by Parkin- LRRK2-mutations, α-
synuclein and MPTP/MPP+ has also been previously reported [64, 88, 244]. In contrast, other 
reports have shown that AMPK mediates dopaminergic cell death induced by rotenone and 6-
OHDA [164, 342]. Contradictory results have also been reported regarding the role of AMPK in 
α-synuclein aggregation and toxicity [88, 151]. AMPK is a central regulator of cellular 
metabolism via modulation of a myriad of processes. Thus, differences between the roles of 
AMPK in dopaminergic cell death induced by different PD-related insults might be related to 
distinct processes being regulated by AMPK, or to the diverse metabolic cues involved in cell 
death or survival. 
Glycolysis has been recently demonstrated to be directly regulated by PD-genes. Glycolysis 
generates methylglyoxal (MGO) as a byproduct from the metabolism of glyceraldehyde 3-
phosphate and dihydroxyacetone phosphate (DHAP) (Figure 2.4). MGO is a potent glycative 
agent that readily reacts with lipids, nucleic acids and protein lysines / arginines to form 
advanced glycation end products (AGEs). MGO also induces mitochondrial dysfunction and is 
29 
 
detoxified by the glyoxalase system through the sequential activity of glyoxalase-1 (GLO1) and 
GLO2 using GSH as a co-factor (Figure 2.4) [8, 79, 303]. An increase in AGEs has been 
reported in PD [324]. MGO is actually a precursor for 1-acetyl-6, 7- dihydroxyl-1, 2, 3, 4-
tetrahydroisoquinoline (ADTIQ), a dopamine (DA)-derived tetrahydroisoquinoline (TIQ) toxin that 
is also found in PD brain tissue [339]. GLO1 converts the intermediary hemithioacetal 
(spontaneous reaction of GSH with MGO) to lactoyl-GSH, which is then metabolized to D-
lactate by GLO2 that also recycles GSH (Figure 2.4). The activity of GLOs is higher in 
astrocytes than neurons [8], and is inhibited by glutathionylation (mixed disulfide bond formation 
between a protein cysteine and GSH) [37]. MGO formation seems to occur primarily in 
astrocytes as neurons have low rates of glycolysis, are very sensitive to MGO and GLO1 
inhibition, and when upregulated, the glyoxylase system fails to protect them against MGO [8]. 
These observations actually correlate with the higher expression of DJ-1 in astrocytes when 
compared to neurons [25], and the discovery that DJ-1 is a cofactor-independent GLO III 
system (Figure 2.4) [179]. In addition to contributing to the detoxification of MGO, DJ-1 has 
been proposed to metabolize MGO and glyoxal (a byproduct from fatty acid peroxidation) to 
generate D-lactate and glycolate, respectively, and that these metabolites contribute to the 
maintenance of mitochondrial function [316]. Parkin was also recently shown to regulate 
glucose metabolism via ubiquitination of pyruvate kinase M1 and PKM2 that results in a 
decrease in their enzymatic activity (Figure 2.3) [198].  
An increased oxidation (4-HNE adduct formation) of the glycolytic enzymes glyceraldehydes 3-
phosphate dehydrogenase (GAPDH), enolase 1 and aldolase A was found in the frontal cortex 
from patients with PD, and dementia with Lewy bodies (DLB) [114]. These glycolytic enzymes 
have been reported to be metastable and thus, prone to interact with and potentially become 
sequestered by amyloid-like structures such as -synuclein fibrils (Figure 2.3) [248, 340]. 
GAPDH has been shown to directly regulate -synuclein aggregation and apoptotic neuronal 
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cell death, which appears to be independent from its role in glycolysis. Glucose phosphate 
isomerase 1 (GPI-1) was recently demonstrated to exert a protective effect against proteotoxic 
stress induced by -synuclein in dopaminergic neurons and this effect was shown to be linked 
to glycolysis (Figure 2.2) [168]. We have observed that the mechanism by which -synuclein 
enhances metabolic dysfunction induced by environmental toxicants is linked to an impairment 
of glycolysis [14]. Accordingly, other reports have reported a possible interaction between -
synuclein and glycolytic enzymes such as aldolase [153, 222]. Conversely, it has been 
previously reported that -synuclein knockdown increases glycative stress [169]. 
3.3.2. Tricarboxylic Acid Cycle 
A dysfunction in the tricarboxylic acid (TCA or Krebs) cycle has been reported in PD brains [5, 
109]. In particular, a decrease in the activity of the 2-oxoglutarate (-ketoglutarate) 
dehydrogenase (OGDH or KGDH) is found in PD brains (Figure 2.8) [109]. Oxidative 
inactivation of aconitase has been shown to be induced by Complex I inhibitors, paraquat and 
PINK1 mutations [46, 93, 157, 193, 229]. It has been demonstrated that inactivation of 
aconitase by oxidative stress can be compensated by OGDH, which allows glutamate to fuel the 
TCA cycle. This likely occurs because aconitase is more sensitive to oxidative damage than 
OGDH [318]. In contrast, oxidative stress induced by MAO was reported to preferentially target 
Complex I and OGDH (Figure 2.8) [210]. 
3.3.3. Nicotinamide Adenine Dinucleotide Metabolism 
Nicotinamide adenine dinucleotide (NAD+) participates in many biological reactions involved in 
energy metabolism, DNA repair and transcription. NAD+ is required for the oxidation of 
glyceraldehyde 3-phosphate to 1,3-biphosphoglycerate by glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) in glycolysis (Figure 2.3). In the TCA cycle, NAD+ is a substrate for: 
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1) the oxidative decarboxylation of isocitrate to oxoglutarate (-ketoglutarate) by IDH3; 2) 
pyruvate / oxoglutarate decarboxilation to thiamine phyrophosphate by pyruvate / oxoglutarate 
dehydrogenase (PDH / OGDH) that is required for the formation of acetyl / succinyl coenzyme A 
(CoA); and 3) the oxidation of malate to oxalacetate (Figure 2.8). NAD+ is also used to transfer 
reducing equivalents from NADH to NADP+ regenerating NADPH by NNT (Figure 2.7). The 
resultant reduced NADH is reoxidized in the cytosol by either the activity of lactate 
dehydrogenase (LDH) (Figure 2.3) or glycerol 3-phosphate dehydrogenase (GPDH), and by 
Complex I in the mitochondria (Figure 2.9). NAD+ is also consumed by poly (ADP-ribose) 
polymerase-1 (PARP-1) during DNA-damage repair (Figure 2.5). Contradictory reports exist 
regarding the role of PARP-1 genetic variants in PD [40, 140], but a number of studies have 
suggested that PARP-1 activation upon PD-related insults leads to energy depletion associated 
to the consumption of ATP by the NAD+ salvage pathway, and subsequent neuronal cell loss 
with necrotic characteristics (Parthanatos) [143, 144, 164, 181, 185, 195, 211, 252, 338, 350]. 
Parthanatos might be a secondary or complementary cell death mechanism to apoptosis in PD 
[334]. NAD+ siphoning by PARP-1 can also have an impact on glycolysis, but this possibility has 
not been explored. In contrast, it has been demonstrated that PARP-1 activity has a protective 
role in neuronal cell death under mild and chronic oxidative stress conditions due to its role in 
oxidative-DNA damage repair [84]. Accordingly, we have observed that inhibition of PARP-1 
enhances dopaminergic cell death induced by paraquat, its synergism with -synuclein, and 6-
OHDA toxicity as well (unpublished results). Ribose 5-phosphate from the PPP is also used for 
ADP-ribose synthesis (Figure 2.5). Thus a link between carbon flux through the PPP and DNA 
damage repair by PARP-1 in PD-related oxidative damage is also plausible. 
Acetyl-CoA, succinyl-CoA and malonyl-CoA are used as substrates for post-translational Lys 
acylation (acetylation, succinylation and malonylation). Sirtuins (SIRT) deacetylase proteins by 
transferring the acetyl group using NAD+ as a co-substrate (Figure 2.6 and 2.7). Sirtuins 
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regulate gene transcription by histone deacetylation, but proteins other than histones are also 
targeted by sirtuins [250]. Deacetylation of mitochondrial proteins within the ETC, the TCA 
cycle, and pyruvate metabolism by SIRT3 regulates metabolic function (Figure 2.8) [128, 269]. 
SIRT3 also regulates mitochondrial dynamics and biogenesis in response to oxidative stress via 
the forkhead transcription factor FOXO3 [319]. Knockout of mitochondrial SIRT3 increases the 
acetylation of multiple Complex I components and reduces its activity and energy production [6]. 
Similarly, IDH2 and MnSOD activity is enhanced by deacetylation via SIRT3 [60, 353]. NAD+ 
consumption by SIRT1 is contended by PARP-1 activity demonstrating the metabolic 
competitiveness for NAD+ consumption [24]. SIRT5 has NAD+-dependent desuccinylation and 
demalonylation activity and also regulates glycolysis, mitochondrial metabolism, ATP synthesis 
and respiration [43, 245, 268]. SIRT3 exerts a protective effect against rotenone induced toxicity 
in vitro, but other reliable evidence regarding the role of sirtuins in PD does not currently exist 
[357]. 
NAD+ consumption by PARPs and sirtuins generates nicotinamide (NAM), which is recycled 
back to NAD+ by the salvage pathway. First, nicotinamide phosphoribosyltransferase (NAMPT) 
catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to generate 
nicotinamide mononucleotide (NMN). Then, nicotinamide mononucleotide adenylyltransferase 
(NMNAT) catalyzes the condensation of NMN or nicotinic acid mononucleotide (NaMN), the 
precursor of NAD+ de novo synthesis, to form NAD+ or nicotinic acid mononucleotide (NaAD), 
respectively, while consuming ATP. NaAD requires further amidation to generate NAD+ [116]. 
Nicotinamide and NMN supplementation restores ATP, mitochondrial function and protects 
against 6-OHDA- MPP+- or rotenone-induced toxicity [148, 205, 361]. We have observed that 
while PARP-1 activity protects against paraquat toxicity in dopaminergic cells, targeted 
overexpression of NAMPT to the cytosol or mitochondria fails to do so (unpublished data), but 
the effect of NAD+ precursors has not been evaluated yet. 
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NAD+ is also a substrate for aldehyde dehydrogenases (ALDH). Cytosolic ALDH1A1 has been 
reported to be specifically located in dopaminergic neurons in the SNpc and to be involved in 
the metabolism of 3,4-dihydroxyphenylacetaldehyde (DOPAL), a toxic oxidative by product from 
dopamine deamination, to 3,4-dihydroxyphenylacetic acid (DOPAC) (Figure 3.5). ALDH1A1 
and the mitochondrial ALDH2 are also involved in the metabolism of 4-HNE (Figure 3.6) [358]. 
Lipid peroxidation byproducts and mitochondrial / environmental toxins inhibit ALDH activity [98, 
99, 187, 270]. Importantly, the inhibition of ALDH activity by rotenone is directly associated with 
decreased NAD+ availability [113, 187, 232]. ALDH1A1 is downregulated in PD brains and 
ALDH1A1 deficiency is linked to an increase in -synuclein induced toxicity [196]. Interestingly, 
inihibition or downregulation of ALDH activity potentiates the toxicity of rotenone but not MPP+ 
[172, 196]. Age-dependent loss of dopaminergic neurons in the substantia nigra is observed in 
mouse lacking both ALDH1A1 and ALDH2, but not ALDH1A1 alone [15, 335]. 
4. Conclusions and Perspectives 
Mitochondrial dysfunction has been well recognized and established as a causative mediator of 
PD pathogenesis. Mitochondrial dysfunction has also been highlighted as the main reason 
behind energy failure and oxidative stress in dopaminergic cells leading to their progressive 
degeneration. However, up till now, therapeutic approaches aimed at either preventing 
(mitochondrial) ROS formation and oxidative damage, or supplementing energy “fuel” to the 
brain have for the most part, failed to stop or ameliorate PD progression. We and others have 
demonstrated that dopaminergic cell death associated with PD-risk factors (genes and 
environmental exposures) is mediated by a dysfunction in both bioenergetics and redox 
homeostasis coupled to alterations in central carbon metabolism. In this review, we have aimed 
to provide an integrated view between bioenergetics, redox homeostasis, and central carbon 
metabolism and their potential role in dopaminergic degeneration (and glial dysfunction) in PD. 
34 
 
Taken together these findings strengthen the idea that PD is a complex metabolic disorder that 
cannot be simplistically and independently explained by either oxidative stress or energy failure. 
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Figure Legends 
 
Figure 1. Redox homeostasis and metabolic coupling between neurons and glia. Redox 
and metabolic homeostasis is carried out by a complex interaction between neurons, glia and 
the extracellular microenvironment. 1.1. Glucose and lactate from blood circulation cross the 
blood brain barrier (BBB) through the GLUT1 (glucose transporter 1) and MCT1 
(monocarboxylate transporter 1) transporters. Lactate is mainly taken up by neurons, while 
glucose is thought to be preferentially consumed by glial cells. 1.2 Neuronal ATP generation is 
dependent on oxidative phosphorylation, while glucose metabolism is primarily directed towards 
the PPP to generate NADPH required for antioxidant defense. Energy failure in PD is expected 
to impair a number of ATP-dependent processes that include: a) protein quality control 
mechanisms, including protein folding and protein aggregate (⍺-synuclein) degradation via the 
UPS and autophagy; b) transport of mitochondria across the axon and dendritic terminals (See 
1.5); c) dopamine and glutamate capture into vesicles; and d) maintenance of ionic gradients 
and plasma membrane potential during synaptic transmission. 1.3. Glycolysis in astrocytes 
exceeds energy demands and thus lactate is shuttled as an energy substrate to neurons, which 
have a limited ability to upregulate glycolysis in response to mitochondrial dysfunction as it 
occurs in PD. Glucose flux to the TCA cycle is reduced in astrocytes due to phosphorylation of 
PDH. Astrocytes are able to store glucose in the form of glycogen. Glutamate (Glu) uptake from 
the inter-synaptic space via EAATs prevents excytotoxicity and facilitates neurotransmitter 
recycling via the synthesis of glutamine (Gln) that is also shuttled to neurons. In addition, Glu 
exchange for Cystine (that is reduced to Cysteine [Cys] inside the cell) via xCT (or Xc-), 
maintains Cys supply for de novo GSH synthesis. Furthermore, Nrf2 activation in response to 
oxidative stress promotes GSH synthesis, which is also released to provide precursors for its de 
novo synthesis in neurons (See 1.5). Astrocytes also have the capacity to use oxidize FFA to 
fuel mitochondria but its functional relevance is unclear. 1.4. Oligodendrocytes also shuttle 
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lactate as energy fuel to myelinated axons. 1.5. In neurons, Nrf2 is repressed by methylation. 
Nevertheless, upregulation of antioxidant defenses is dependent on neuronal activity and the 
activation of ATF4 and AP-1 transcription factors. 1.6. Environmental toxicants, -synuclein 
oligomers, and cytokines activate microglia and induce oxidative stress. Importantly the pro-
inflammatory M1 phenotype of activated microglia has been reported to be associated to a 
switch in their metabolism from oxidative phosphorylation to glycolysis that also enhances 
carbon flux to the PPP. 
Figure 2. Interaction of Parkinson disease-related genes and risk factors with 
bioenergetics and central carbon metabolism.  2.1. BDNF released by glial cells (and 
activation of the tropomyosin receptor kinase B [TrkB]) has protective effects in dopaminergic 
cells that can potentially be associated with the regulation of neuronal bioenergetics. 2.2 In 
astrocytes, energy can be stored as glycogen or it can be metabolized via glycolysis to meet 
energy demands. Glucose metabolism is also directed to lactate production that can be shuttled 
to neurons. In neurons PFKFB3 is constantly degraded and thus, they depend primarily in 
oxidative phosphorylation to meet their energy demands. GPI has been demonstrated to exert a 
protective effect against -synuclein toxicity via glycolysis. 2.3. Downstream the glycolytic 
pathway a number of enzymes have been shown to be altered / regulated in PD and by PD-
related risk factors. Aldolase (ALDO), GAPDH and enolase (ENO) are found aggregated and 
oxidized in PD. Amyloid-like -synuclein fibrils are expected to interact with and likely inhibit 
metastable glycolytic enzymes such as ALDO. Other groups have reported on the role of Parkin 
inhibiting PKM activity by ubiquitination. 2.4. Spontaneous generation of methylglyoxal is 
thought to account for 0.1-0.4% of glycolytic flux. Accumulation of AGEs and dopamine-related 
methylglyoxal derivatives is linked to PD. DJ-1 is a cofactor-independent GLO III system that 
detoxifies methylglyoxal while also generating D-lactate that can contribute to the maintenance 
of mitochondrial function. DJ-1 is a redox-sensitive protein whose protective effects against PD-
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related insults can be impaired by oxidative stress. 2.5 In neurons, glucose is primarily 
metabolized via the PPP to generate NADPH that provides reducing equivalents for antioxidant 
defense. Astrocytes have higher levels of NADPH and G6PD, and in glial cells, NADPH also 
has a pro-oxidant role by providing reducing equivalents for the generation of ROS by NOX and 
NOS. In addition, the ribose-5-P from the PPP is used for the generation ADP-ribose that is 
used during DNA-damage repair as a substrate for PARP-1 mediated ADP-ribosylation. NADPH 
is also regenerated by IDH1 in cytosol (2.6) and in the mitochondria by Nnt (2.7), and both 
systems have been reported to protect against PD-related insults MPP+ and paraquat. 2.8. 
Alterations in the TCA cycle have also been found associated with PD. In the mitochondria, 
pyruvate decarboxylation by PDH is a necessary step for the generation of acetyl-CoA and Mn 
(manganese), a PD-risk factor has been reported to inhibit its activity. Aconitase (ACO) 
inactivation by oxidative stress is a biomarker of oxidative damage induced by PD-related 
insults or PINK1 mutants, while a decrease in OGDH is found in PD.  2.9. A decrease in 
Complex I activity is found in PD. In addition Complex I has been reported to be targeted by 
environmental toxicants acting as Complex I inhibitors or inducing oxidative stress. PD-related 
genes DJ-1 and PINK1 regulate Complex I activity via direct interaction or phosphorylation of its 
subunits. 2.10. The mitochondrial shuttles enable electrons and precursors transport across the 
inner membrane. Glutamate is metabolized to glutamine by GS an enzyme exclusively present 
in the astrocytes. Glutamine is shuttled from astrocytes to neurons where it is metabolized back 
to glutamate by GLS. A number of metabolites act as substrates for the activity of signaling 
proteins (highlighted in green circles). Prolyl hydroxylase (PDH)-dependent hydroxylation of 
HIF-1 requires 2-oxoglutarate. 2.11. One-carbon metabolism of serine to glycine and cysteine 
(via the transsulfuration pathway) contribute to the formation of GSH. 2.12. Neurons very poorly 
metabolize FFA to obtain energy due the high O2 demand and resultant generation of 
superoxide anion (O2
•-) from β-oxidation. However, 20% of total adult brain energy comes from 
FFA oxidation, mostly in astrocytes, but its functional relevance is unclear. Enzymes highlighted 
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in blue circles are those within central carbon metabolism found to be modulated by oxidative 
stress and PD-related risk factors. PD-related genes are highlighted in red circles. Abbreviations 
and enzyme commission (EC) numbers for enzymes involved in central carbon metabolism: 
ACC, Acetyl-CoA carboxylase [EC: 6.4.1.2]; ACLY, ATP-citrate synthase [EC:2.3.3.8]; ACO, 
Aconitase [EC:4.2.1.3]; ALDO (A/B), Fructose-bisphosphate aldolase [EC:4.1.2.13]; cAspAT, 
Aspartate aminotransferase, cytoplasmic [EC:2.6.1.1 2.6.1.3]; mAspAT, Aspartate 
aminotransferase, mitochondrial [EC:2.6.1.1 2.6.1.7]; AR, aldose reductase [1.1.1.21]; CBS, 
Cystathionine beta-synthase [EC: 4.2.1.22]; CPT1, carnitine O-palmitoyltransferase 1 (CPT1 or 
2 (CPT2) [EC: 2.3.1.21]; CS, Citrate synthase [EC:2.3.3.1]; CTH, Cystathionine gamma-lyase 
[EC: 4.4.1.1]; ENO, Enolase [EC:4.2.1.11]; FBP, fructose-1,6-bisphosphatase I [EC:3.1.3.11]; 
FUM, Fumarate hydratase [EC:4.2.1.2]; G3PP; Glucose-3-phosphate permease [EC: ]; G6PD, 
Glucose-6-phosphate 1-dehydrogenase [EC:1.1.1.49]; GAPDH, Glyceraldehyde 3-phosphate 
dehydrogenase [EC:1.2.1.12]; GCL, Glutamate cysteine ligase [EC: 6.3.2.2]; GDH, Glutamate 
dehydrogenase, [EC: 1.4.1.3]; GLO1, Glyoxalase 1 or Lactoylglutathione lyase [EC:4.4.1.5]; 
GLO2, Glyoxalase 2 or Hydroxyacylglutathione hydrolase [EC 3.1.2.6]; GLS, Glutaminase [EC: 
3.5.1.2]; GPI, Glucose-6-phosphate isomerase [EC:5.3.1.9]; GS, Glutamine synthetase 
[EC:6.3.1.2]; GSS, glutathione synthetase [EC: 6.3.2.3]; HK, hexokinase [EC:2.7.1.1]; IDH1, 
Isocitrate dehydrogenase 1 (NADP+), soluble [EC:1.1.1.42]; IDH3, isocitrate dehydrogenase 3 
(NAD+); LDH, L-lactate dehydrogenase [EC:1.1.1.27]; MDH, Malate dehydrogenase 
[EC:1.1.1.37]; OGDH, 2-Oxoglutarate dehydrogenase, [EC:1.2.4.2]; SCS, Succinyl-CoA 
synthetase [EC:6.2.1.4 6.2.1.5]; PC, Pyruvate carboxylase [EC:6.4.1.1]; PGD, 6-
phosphogluconate dehydrogenase [EC:1.1.1.44]; PDH, Pyruvate dehydrogenase [EC:1.2.4.1]; 
PGK, phosphoglycerate kinase [EC:2.7.2.3]; PGM, Phosphoglucomutase [EC:5.4.2.2]; PFK, 6-
phosphofructokinase 1 [EC:2.7.1.11]; PFKFB3, 6-phosphofucto-2-kinase/fructose-2,6-
biphosphatase 3 [EC:3.1.3.46]; PKM, Pyruvate Kinase [EC:2.7.1.40]; RPI, Ribose 5-phosphate 
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isomerase A [EC:5.3.1.6]; SDH, Succinate dehydrogenase [EC:1.3.5.1]; SHMT, Serine 
hydroxymethyltransferase [EC 2.1.2.1]; TPI, triose-phosphate isomerase [EC:5.3.1.1]. 
Figure 3. Bioenergetic requirements of antioxidant systems. Energy failure and ROS are 
the main consequences associated with mitochondrial dysfunction in PD. 3.1a. Electron leakage 
from the mitochondria leads to one electron reduction of O2 to O2
- that can be dismutated by 
SODs to H2O2. 
NO can outcompete SODs reacting with O2
- to generate -ONOO. 3.1b. In the 
plasma membrane O2
-- can be generated by NOXs. 3.2. In the presence of metals such as Fe, 
H2O2 and O2
- generate OH through the Fenton/Haber-Weiss reaction. In PD, -synuclein, 
neuromelanin and Fe-S clusters are important pools of Fe. 3.3. Catalase and Prxs catalyze 
H2O2 degradation. The Trx/TrxR system supplies reducing equivalents for most Prxs. Prx 
hyperoxidation is reversed by Srx.  3.4a. Gpxs detoxifies peroxides using GSH which is reduced 
back from GSSG by GR using NADPH. 3.4b. GSH also detoxifies electrophiles (DAQ and 4-
HNE) via the action of GSTs, and these adducts can be transported outside of the cell to 
become eliminated by the activity of MRP proteins. 3.5. In the cytosol, dopamine (DA) becomes 
auto-oxidized in the presence of Fe generating DAQs and ROS.  DA metabolism by MAO also 
generates ROS and DOPAL, which is further metabolized by ALDHs. 3.6. ALDHs also detoxify 
4-HNE into 4-hydroxy-2-nonenoic acid (HNA) that is metabolized by cytochrome P450 enzymes 
(P450). 3.7. Oxidative stress triggers antioxidant response elements (AREs)-regulated gene 
transcription by Nrf2, which promotes GCLC/GCLM, CuZnSOD and MnSOD transcription. 3.8. 
A number of antioxidant systems and ROS generating enzymes utilize reducing equivalents 
from NADPH (in blue letters) that is regenerated by enzymes such as G6PD, and synthesized 
de novo via the phosphorylation of NAD+ by NAD-kinase (NADK). Thus, antioxidant systems are 
tightly coupled to NAD+ and central carbon metabolism. In addition, many antioxidant enzymes 
and stress responses (DNA-damage repair and the transcription of antioxidant enzymes by 
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Nrf2) require energy consumption (ATP, highlighted in dark red) demonstrating that redox 
homeostasis is tightly coupled to bioenergetics and cell metabolism. 
Figure 4. Mitochondrial dynamics and biogenesis are coupled to oxidative stress and 
energy failure. 4.1. Mitochondrial fusion rescues “moderately” dysfunctional mitochondria by 
enabling their “damaged” content to be mixed between neighboring mitochondria. Fusion is 
impaired by the ubiquitination of Mfns by PINK1 and Parkin (See 4.4). 4.2. Fission, transforms 
damaged mitochondria into a form suitable for engulfment by mitophagy, and it has been 
suggested to facilitate transport of mitochondria into terminals (See 4.6).  4.3. Parkin 
translocates to the mitochondria and interacts with PINK1 in response to a loss in membrane 
potential (ΔΨm) induced by energy failure or oxidative damage. VDAC1 is polyubiquitinated and 
recruits p62, which in turn interacts with LC3 at the autophagosomal membrane. Finally, 
engulfed damaged mitochondria are degraded after the autophagosome fuses with the 
lysosome and lysosomal hydrolases are released within the fused autolysosome. 4.5. It has 
also been proposed that Parkin and PINK1 induce the formation of mitochondrial derived 
vesicles that translocate damaged mitochondrial proteins into lysosomes. 4.6. Transportation of 
mitochondria to axonal and dendritic terminations is essential to meet energy demands 
associated with synaptic transmission. PINK1 and Parkin mediate phosphorylation, 
ubiquitination and degradation of Miro leading to the detachment of mitochondria from 
microtubules. 4.7. Oxidative stress and energy failure activate PGC-1α to stimulate 
mitochondrial biogenesis. Energy failure in PD is expected to impair transport of mitochondria 
into terminals, and the mitochondrial quality control mechanisms mitophagy and UPS. 4.4. The 
proteasome has also been proposed to translocate to the mitochondria and mediate the 
degradation of damaged proteins. (ATP consumption is highlighted in red). 
 
 




